SLC6A4

Sodium-dependent serotonin transporter · P31645 · SLC6A4 on Sugi Atlas →

807,103 patent compounds predicted against SLC6A4, 427,817 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Sulfuric Acid (SCHEMBL4224)	0.87	20/20
Hydrochloric Acid (SCHEMBL1375)	0.66	20/20
Oxalic Acid (SCHEMBL9746)	0.87	19/20
Cadaverine Tartrate (SCHEMBL3757)	0.64	19/20
SCHEMBL2793	0.57	19/20
Oxalic Acid (SCHEMBL3729)	0.53	19/20
Hydrochloric Acid (SCHEMBL2049)	0.71	18/20
Hydrochloric Acid (SCHEMBL2283)	0.69	18/20
Hydrochloric Acid (SCHEMBL1864)	0.66	18/20
Hydrochloric Acid (SCHEMBL2314)	0.65	18/20
Hydrochloric Acid (SCHEMBL2616)	0.61	18/20
Hydrochloric Acid (SCHEMBL2448)	0.61	18/20
Hydrochloric Acid (SCHEMBL2287)	0.59	18/20
SCHEMBL2644	0.57	18/20
SCHEMBL2504	0.90	17/20
Hydrochloric Acid (SCHEMBL2105)	0.88	17/20
Hydrochloric Acid (SCHEMBL2216)	0.88	17/20
SCHEMBL2468	0.65	17/20
SCHEMBL2150	0.64	17/20
SCHEMBL1822	0.63	17/20

Clinical trials — most relevant to SLC6A4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy	PHASE4	COMPLETED
Functional Connectivity in Mood Regulating Circuit In Bipolar Depression and Mania	PHASE4	COMPLETED
Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression	PHASE4	COMPLETED
Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype	PHASE4	UNKNOWN
Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities	PHASE3	COMPLETED
Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder	PHASE2/PHASE3	COMPLETED
Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)	PHASE2	COMPLETED
Matching Genotypes and Serotonergic Medications for Alcoholism	PHASE1	COMPLETED
Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)	PHASE1	COMPLETED
Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation	EARLY_PHASE1	UNKNOWN
Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy	nan	NOT_YET_RECRUITING
Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients	nan	UNKNOWN
Multimodal Neurobiological Approaches to Explore the Gene-Environment Interactions in ADHD	nan	COMPLETED
Age-17 Follow-up of Home Visiting Intervention	nan	COMPLETED
Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder	nan	COMPLETED
Estrogen Receptor 1 Gene Polymorphism Frequency in Fibromyalgia Syndrome	nan	COMPLETED
Genecept Assay and Adverse Effects of Antidepressants	nan	COMPLETED
A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.	nan	UNKNOWN
Atomoxetine PBPK-PD Clinical Study	nan	COMPLETED
Examination of Brain Serotonin Receptors in Patients With Mood Disorders	nan	COMPLETED
Childhood Adversity, Genetic Polymorphisms and Stress in First Onset Major Depression	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Optimizing Medication Management for Mothers With Depression	nan	COMPLETED
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration	nan	COMPLETED
The Role of Sex Steroids and Serotonin Brain Dynamics in Perinatal Mental Health	nan	COMPLETED
PET Whole Body Distribution Studies Using [11C]CUMI	nan	COMPLETED
Serotonin Function During Depression	nan	COMPLETED
Antidepressants, Emotions and Personality	nan	COMPLETED
Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive Disorder	nan	WITHDRAWN
Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC6A4 binder may also engage these)

Protein	Name	Similarity
Q9MYX0	—	1.000	Q9MYX0 →
P31652	—	1.000	P31652 →
Q9XT49	—	1.000	Q9XT49 →
P31649	—	1.000	P31649 →
Q61327	—	1.000	Q61327 →
P23977	—	1.000	P23977 →
P51143	—	1.000	P51143 →
Q03614	—	1.000	Q03614 →
P31646	—	1.000	P31646 →
Q60857	—	1.000	Q60857 →
O88575	—	1.000	O88575 →
SLC6A11	Sodium- and chloride-dependent GABA transporter 3	1.000	landscape →
O35899	—	1.000	O35899 →
O18875	—	1.000	O18875 →
SLC6A6	Sodium- and chloride-dependent taurine transporter	1.000	landscape →
Q9GJT6	—	1.000	Q9GJT6 →
Q9UN76	—	1.000	Q9UN76 →
P31647	—	1.000	P31647 →
B4JMC1	—	1.000	B4JMC1 →
SLC6A13	Sodium- and chloride-dependent GABA transporter 2	1.000	landscape →
P28570	—	1.000	P28570 →
O35316	—	1.000	O35316 →
P31661	—	1.000	P31661 →
P31650	—	1.000	P31650 →
P51905	—	1.000	P51905 →
SLC6A3	Sodium-dependent dopamine transporter	1.000	landscape →
A7Y2W8	—	1.000	A7Y2W8 →
B4NDL8	—	1.000	B4NDL8 →
Q8VDB9	—	1.000	Q8VDB9 →
P48029	—	1.000	P48029 →